The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer.

Chronic inflammation is now recognized as one of the major risk factors and molecular hallmarks of chronic prostatitis, benign prostatic hyperplasia (BPH), and prostate tumorigenesis. However, the molecular mechanisms by which chronic inflammation signaling contributes to the pathogenesis of these prostate diseases are poorly understood. Previous efforts to therapeutically target the upstream (e.g., TLRs and IL1-Rs) and downstream (e.g., NF-κB subunits and cytokines) inflammatory signaling molecules in people with these conditions have been clinically ambiguous and unsatisfactory, hence fostering the recent paradigm shift towards unraveling and understanding the functional roles and clinical significance of the novel and relatively underexplored inflammatory molecules and pathways that could become potential therapeutic targets in managing prostatic diseases. In this review article, we exclusively discuss the causal and molecular drivers of prostatitis, BPH, and prostate tumorigenesis, as well as the potential impacts of microbiome dysbiosis and chronic inflammation in promoting prostate pathologies. We specifically focus on the importance of some of the underexplored druggable inflammatory molecules, by discussing how their aberrant signaling could promote prostate cancer (PCa) stemness, neuroendocrine differentiation, castration resistance, metabolic reprogramming, and immunosuppression. The potential contribution of the IL1R-TLR-IRAK-NF-κBs signaling molecules and NLR/inflammasomes in prostate pathologies, as well as the prospective benefits of selectively targeting the midstream molecules in the various inflammatory cascades, are also discussed. Though this review concentrates more on PCa, we envision that the information could be applied to other prostate diseases. In conclusion, we have underlined the molecular mechanisms and signaling pathways that may need to be targeted and/or further investigated to better understand the association between chronic inflammation and prostate diseases.

Equine Influenza Virus and Vaccines.

Equine influenza virus (EIV) is a constantly evolving viral pathogen that is responsible for yearly outbreaks of respiratory disease in horses termed equine influenza (EI). There is currently no evidence of circulation of the original H7N7 strain of EIV worldwide; however, the EIV H3N8 strain, which was first isolated in the early 1960s, remains a major threat to most of the world's horse populations. It can also infect dogs. The ability of EIV to constantly accumulate mutations in its antibody-binding sites enables it to evade host protective immunity, making it a successful viral pathogen. Clinical and virological protection against EIV is achieved by stimulation of strong cellular and humoral immunity in vaccinated horses. However, despite EI vaccine updates over the years, EIV remains relevant, because the protective effects of vaccines decay and permit subclinical infections that facilitate transmission into susceptible populations. In this review, we describe how the evolution of EIV drives repeated EI outbreaks even in horse populations with supposedly high vaccination coverage. Next, we discuss the approaches employed to develop efficacious EI vaccines for commercial use and the existing system for recommendations on updating vaccines based on available clinical and virological data to improve protective immunity in vaccinated horse populations. Understanding how EIV biology can be better harnessed to improve EI vaccines is central to controlling EI.

In vivo Studies on the Phytotherapeutic and Fertility Effects of Dracaena Arborea Extract in Alloxan-induced Type 1 Diabetic Male Rats.

Aim: This study was designed to explore and exploit the phytotherapeutic and fertility effects of ethanolic leaf extract of Dracaena arborea in type-1 Alloxan-induced diabetic rats. The phytotherapeutic effects of Dracaena arborea on hematological parameters, appetite, spermiogram, histological architecture and histomorphometrics (stereology) of testicular and/or pancreatic tissues of treated and untreated rats were carried out. Place and Duration of Study: Department of Anatomy, College of Medicine, Lagos State University, Ikeja, Lagos, Nigeria, between October, 2012 and February, 2013. Methodology: 24 healthy normal male rats were recruited for this study. They were divided into four groups in a randomized trial; with group A consisting of non-diabetic healthy rats that received only the vehicle (0.5 mg/kg of 2% acacia solution); while group B, C & D was injected intraperitoneally with a single dose of Alloxan monohydrate (ALX) at 100 mg/kg prior to DAE treatment. Groups C and D were subsequently administered DAE orally 72 hours post administration of ALX, at daily doses of 100 mg/kg and 300 mg/kg respectively. Results: ALX (100 mg/kg) was found to induce type 1 diabetic conditions in the rats, demonstrated by the significant increase (P < 0.05) in the glucose levels, and a decline in appetite (water and food intakes). Conversely, administration of DAE at 100 and 300 mg/kg revealed significant dose and time- dependent increase (P < 0.05) in glucose tolerance and appetite (water and food intakes) in DAE treated groups compared to the untreated or ALX treated only group. Significant normalization (P < 0.05) of red blood cell count, packed cell volume and Hemoglobin levels were also observed in diabetic rats treated with the 100 mg/kg and 300 mg/kg DAE. In addition, testicular and pancreatic histopathological profiles of both DAE treated groups show evidences of appreciable normalization of ALX-induced pathology. Conclusion: Our findings indicates that DAE may offer great therapeutic benefit in the treatment of type-1 diabetes mellitus and normalizing testicular dysfunction or infertility in diabetic patients.